Specialists suggest the hypothalamus releases gonadotropin-releasing hormones (GnRH), which are responsible for the production and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The endocrine system’s activity levels are modest throughout younger years but extremely high during older ones.
Scientists speculate that GnRH activity is required for fertilization in regular organisms. GnRH pulsatility declines with age, malnutrition, and diseases such as hypogonadotropic hypogonadism and polycystic ovarian syndrome (PCOS), negatively affecting fertility. [i]
Research suggests that Triptorelin is a synthetic peptide potentially contributing to GnRH deficit or inefficiency research with strong biocompatibility.
Triptorelin Peptide Overview
According to research studies, Triptorelin is a ten-amino-acid peptide that may mimic the actions of natural gonadotropin-releasing hormones (GnRH). [ii]
Further research suggests that to increase testosterone production in male test subjects and estrogen synthesis in female test subjects; Triptorelin may stimulate the pituitary gland to produce and release the luteinizing hormone (LH) and follicle-stimulating hormone (FSH). [iii]
According to data, the GnRH hormone was first discovered and identified in 1971 by Professor Andrew Schally and his colleagues, who also established the decapeptide amino acid sequence. In 1977, Professor Schally received the Nobel Prize for this work. [iv]
Triptorelin Mechanism of Action
As clinical studies suggest, Triptorelin is a GnRH analog that may act as an agonist, binding to pituitary receptors to increase LH and FSH production. Studies speculate that the early phase of LH and FSH stimulation might be increased due to this. Reduced LH and FSH secretion occurs due to the downregulation of the receptors, which occurs over time as the receptors become less responsive to the substance.
Research suggests that the decline in follicle-stimulating hormone (LH) and luteinizing hormone (FSH) levels cause a parallel decline in testosterone (in male test subjects) and estrogen (in female test subjects). Ovary and testicular inhibition of steroidogenesis follow this process. [v] Researchers speculate that LH and FSH production may decrease and remain low for the first four weeks after consistently administering the peptide.
Common interactions investigated in research studies, include [vi]:
- Research into prostate cancer
- Research into breast cancer
- Central precocious puberty (CPP)
- Research into Endometriosis
- Immune system restoration
Triptorelin Peptide Research Studies
Triptorelin and Prostate Cancer
Male subjects’ bodies have a tiny gland called the prostate that produces seminal fluid to carry the sperm. [vii] Research speculates that androgen deprivation may be widely used to research prostate cancer. (ADT). Licensed researchers suggest that plasma testosterone may often be lowered
Further studies [viii] speculate that the effectiveness of Triptorelin administration over 1, 3, and 6 months was analyzed retrospectively. The test subjects in this research were male models with prostate cancer. Before the trial, these test subjects had never had prostate cancer treatment or had undergone a full washout. Testosterone levels were measured after 1, 3, 6, 9, and 12 months of peptide being present. The results suggested that plasma testosterone levels of 80%, 92%, 93%, 90%, and 91% of research models were below 20 ng/dl. This result supported the hypothesis that Triptorelin might successfully decrease testosterone levels.
Triptorelin and Endometriosis
Endometriosis is a disorder in which tissue normally found in the uterus develops in places outside of the uterus. Constant abdominal pain, heavy periods, and infertility are some symptoms. [ix]
Female test subjects with endometriosis were given Triptorelin once every four weeks in a randomized controlled experiment [x]. Parameters including symptom alleviation, endometrial size reduction, hormonal impacts, bone mineral density modulations, and regular menstruation were examined to determine the peptide’s effectiveness.
The study suggested that all subjects improved pain-related symptoms after 8 weeks. Further results speculated that all research models showed decreased FH and LSH levels, although cholesterol and triglyceride levels rose modestly.
If you are a researcher interested in purchasing Triptorelin peptide for your clinical studies, you can do so if you click here. Please note that none of the items listed are approved for human or animal consumption. Laboratory research chemicals are only for in-vitro and in-lab use. Any kind of physical introduction is illegal. Only authorized academics and working professionals may make purchases. The content of this article is intended only for instructional purposes.
[i] Tsutsumi, Rie, and Nicholas J G Webster. “GnRH pulsatility, the pituitary response and reproductive dysfunction.” Endocrine journal vol. 56,6 (2009): 729-37. doi:10.1507/endocrj.k09e-185. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307809/
[ii] National Center for Biotechnology Information. PubChem Compound Summary for CID 25074470, Triptorelin. https://pubchem.ncbi.nlm.nih.gov/compound/Triptorelin
[iii] LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Triptorelin. https://www.ncbi.nlm.nih.gov/books/NBK548756/
[iv] Lepor, Herbert. “Comparison of single-agent androgen suppression for advanced prostate cancer.” Reviews in urology vol. 7 Suppl 5 (2005): S3-S12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1477619/
[v] Triptorelin. https://www.drugs.com/ppa/triptorelin.html
[vi] Triptorelin (Intramuscular Route). https://www.mayoclinic.org/drugs-supplements/triptorelin-intramuscular-route/description/drg-20066536
[vii] Prostate cancer. https://www.mayoclinic.org/diseases-conditions/prostate-cancer/symptoms-causes/syc-20353087
[viii] Breul J, Lundström E, Purcea D, Venetz WP, Cabri P, Dutailly P, Goldfischer ER. Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer. Adv Ther. 2017 Feb;34(2):513-523. doi: 10.1007/s12325-016-0466-7. Epub 2016 Dec 27. https://pubmed.ncbi.nlm.nih.gov/28028737/
[ix] Endometriosis Health Center. https://www.webmd.com/women/endometriosis/default.htm
[x] Choktanasiri W, Boonkasemsanti W, Sittisomwong T, Kunathikom S, Suksompong S, Udomsubpayakul U, Rojanasakul A. Long-acting triptorelin for the treatment of endometriosis. Int J Gynaecol Obstet. 1996 Sep;54(3):237-43. https://pubmed.ncbi.nlm.nih.gov/8889631/